I have reviewed many cost analyses on cardiovascular interventions for literature reviews and inclusions as inputs into other costeffectiveness analyses. This paper is among the most detailed and clear that I have read. They include justifications for each of the decisions they made and clear explanation for what is included in each category of costing. They also include a flow chart of the patient's steps through the health system with costing at each stage, which is helpful for the reader unfamiliar with PCI treatments. The limitations were well outlined, particularly that there is likely selection bias, as only 5 institutions agreed to be a part of the study. This manuscript only includes the results of one institution, so it will be interesting to see how the results of all five institutions compare. Overall, however, this is a well-planned, well-articulated costanalysis of PCI, and a timely subject matter.
will continue to escalate with the advancement in medical technologies, as with many other cardiac services. This could be debatable in the event that more cost effective technologies might be developed.
Page 5, Lines 15-18: The authors write that policy makers and healthcare professionals will be interested to gain more insight into the cost variation of performing cardiac procedures such as PCI in different centres. It would be worthwhile to have some detail in how these costs might differ and how this information might be of help to clinical personnel, hospital administrators and other policy makers.
Objectives: a) The challenges faced when implementing costing guidelines are not uncommon in LMICs settings, as the authors have outlines. In such scenarios, it is not uncommon for health economists to make assumptions in their costing methodology, and to ensure that the assumptions that are reasonable and justifiable for that context. This is what the authors have done, so I would be cautious about calling it a modified methodology as there are actually no modifications to the top down costing method used.
b) The authors also present results from only one site. The paper would have more impact if the cost estimates from all 5 sites could be presented, along with a discussion of where the differences in the costs come from, if any. This would also serve as a way of an internal validation of cost estimates and provide more comprehensive information to policy makers. I would recommend including the estimates from all 5 sites.
Study sites: All five facilities are are the tertiary regional referral hospitals that provide full-fledged cardiology and cardiothoracic services. It would be worthwhile to reflect on whether elective PCIs are performed at other types of health facilities, for example, lower tiers of hospitals. If yes, then their exclusion could also limit the generalizability of results. It is also not clear if these 5 hospitals are in urban, rural or peri-urban areas. Table 1 : "Start of PCI operation"-does this refer to when the hospital began to offer this service?
Cost data collection: There is a greater level of detail required about the costs data collection. The most important here is the source of the data and the types of cost-this must be mentioned here, rather than in the section on valuation, to take the reader through the methods in a structured way. This may be presented in a table. It would also be useful to have details about the following points: -Who provided the feedback based on the pilot of the tool? -Who was responsible for data entry, checks and cost allocations? -How was data validated?
Labour, lines 34-43: Was each interventional cardiologist at each of the 5 facilities interviewed to understand their time use? What about the fellows?
Capital: Building and land costs were not taken into consideration. As these are all tertiary facilities, this might be less of an issue but the costs of infrastructure might differ between urban and rural centres and by the level of facility, which would contribute to the cost variation. This information might be useful for policy makers, if they decide to shift services to a specific type of facility, or when they think about cost savings, as mentioned in the introduction by the authors.
The cost of drugs are excluded, for example, local anaesthetics that might be required for PCI procedures. Further, there is no discussion about drug prescription and usage associated with PCIs, for example, inhibitors.
Results: In addition to the point raised above about the partial presentation of results, it would be helpful to know which hospital this is. It would also be useful to have a comparison of the cost estimates with those from other studies.
REVIEWER
Lisandro Colantonio School of Public Health, University of Buenos Aires, Argentina REVIEW RETURNED 02-Mar-2017
GENERAL COMMENTS
Yun et al. describe the design of a costing study in Malaysia. Overall, I found the manuscript interesting, and worthwhile for publication. However, I think that the manuscript should be improved by clarifying the rationale for this manuscript, and focusing on it.
Main comments: 1. The main purpose of this manuscript seems to be to provide an example about a costing exercise (no final results are presented). In that case, I think that providing more details about the costing procedures would be useful for readers. For example, authors could show the total labor cost in the center that they analyzed, and show how they calculated the unit cost reported in Minor comments 3. Abstract. The sentence: "we included only patients who undergo PCI" could be confused for many readers. Stating that patients were included may lead to many readers to think that other kind of costing method was used. There are actually no "patients" included in this study, but rather healthcare centers. I would suggest to change the abstract to indicate that the unit of analysis are healthcare centers, and that the outcome was an elective PCI hospitalization cost.
4. The introduction could be shortened and more focused on the main purpose for this manuscript. For example, a discussion about the burden of CVD in Malaysia seems superfluous if the main purpose of the manuscript is to provide an example about how costs can be estimated in LMIC. I would consider a discussion on the burden of CVD more appropriate if the purpose of the manuscript were to present final results on the costs of PCI.
5. In addition to PCI, there are other conditions that are being costed? It could be valuable for some readers to know that in the future you will be able to present costs for other conditions. These are kind of data that could be very useful for those interested in using the costs that you estimated for future studies. Being able to know the characteristics of the population that you used to estimate the costs would help these researchers to understand whether your results could be generalized to their patients. However, you may have not been able to collect these information, which may be a limitation of this costing method.
11. Table 2 : PCI consumables were reported separately from CL. If so, I would suggest to revise the methods section to identify 3 units of costing: CW, CL and PCI consumables.
12. Figure 1 : There is not arrow going to the PCI consumables box.
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1 Reviewer Name: Elizabeth Brouwer Institution and Country: University of Washington, United States Please state any competing interests: None declared Please leave your comments for the authors below I have reviewed many cost analyses on cardiovascular interventions for literature reviews and inclusions as inputs into other cost-effectiveness analyses. This paper is among the most detailed and clear that I have read. They include justifications for each of the decisions they made and clear explanation for what is included in each category of costing. They also include a flow chart of the patient's steps through the health system with costing at each stage, which is helpful for the reader unfamiliar with PCI treatments. The limitations were well outlined, particularly that there is likely selection bias, as only 5 institutions agreed to be a part of the study. This manuscript only includes the results of one institution, so it will be interesting to see how the results of all five institutions compare. Overall, however, this is a well-planned, well-articulated cost-analysis of PCI, and a timely subject matter.
Thank you for the positive comments. Please see the above explanation after the editorial comments with regard to the full results.
Reviewer: 2 Reviewer Name: Neha Batura Institution and Country: University College London, UK Please state any competing interests: None declared Please leave your comments for the authors below This is a very interesting costing study, and the description of methods used will be quite useful to other researchers working in this area. I have a few suggestions and comments that would improve the impact of the paper, as well as the clarity of the message.
Thank you for the constructive feedback. We have revised the necessary sections as described below.
Page 4, lines 24-26: The authors write that CVD places a huge economic burden on the healthcare system as well as patients. However, it is important to reflect on the fact that globally, even if care for CVD is free or subsidised at public hospitals, there are several direct and opportunity costs borne by patients.
As our study focused on cost from the healthcare perspective, we placed more emphasis on that aspect. However, we have edited the sentence slightly (Page 4 Paragraph 2) as not to dismiss the burden from the social perspective.
Page 5, lines 11-13: The authors write that the cost of PCI provision will continue to escalate with the advancement in medical technologies, as with many other cardiac services. This could be debatable in the event that more cost-effective technologies might be developed.
We have rephrased this section to convey the point as to how cost data and economic evaluation are prerequisite to identify the most cost-effective option in the face of scarcity (Page 5 Paragraph 2).
A short background statement was added in Introduction (Page 5 Paragraph 1) and further explanation was provided in Discussion (Page 18 Paragraph 1).
We agree that this is a valid concern and thus we have either removed or rephrased the term "modified" throughout our manuscript.
Please see above explanation under Editorial comment.
Study sites: All five facilities are the tertiary regional referral hospitals that provide full-fledged cardiology and cardiothoracic services. It would be worthwhile to reflect on whether elective PCIs are performed at other types of health facilities, for example, lower tiers of hospitals. If yes, then their exclusion could also limit the generalizability of results. It is also not clear if these 5 hospitals are in urban, rural or peri-urban areas.
We have clarified this matter in Introduction (Page 5 Paragraph 1) and Methods-Study Site (Page 6). Table 1 : "Start of PCI operation"-does this refer to when the hospital began to offer this service?
Yes. We have rephrased it as "Year of Initiation of PCI service" in Table 1 .
Cost data collection: There is a greater level of detail required about the costs data collection. The most important here is the source of the data and the types of cost-this must be mentioned here, rather than in the section on valuation, to take the reader through the methods in a structured way. This may be presented in a table.
We have added this information in Table 2 .
It would also be useful to have details about the following points: -Who provided the feedback based on the pilot of the tool? -Who was responsible for data entry, checks and cost allocations? -How was data validated?
Please see the edited section on Methods-Cost Data Collection (Page 8).
As the interventional cardiologists in our study team are also the head of cardiology department in each respective centre, they are able to provide an accurate breakdown of time use for different levels of doctors. We have amended the Labour section (Page 9) to clarify this.
We have addressed this as a limitation in the Discussion (Page 17 Paragraph 2).
The drug cost was taken into account-as "Medication" in the original Figure 1 and Table 1 . In the revised manuscript, we have added in a short paragraph for Medication use in Step 3. Valuation of Cost Items (Page 10).
Results: In addition to the point raised above about the partial presentation of results, it would be helpful to know which hospital this is.
The preliminary result in the original manuscript was for Centre I, the semi-corporatized teaching hospital as outlined in Study Sites and Table 1 . We have added in the currency-Ringgit Malaysia (RM) in the new Table 3 .
It would also be helpful to tabulate the % breakdown of the average costs, for example % share of labour, capital, ancillary support, hospital support (all components listed in Table 2 ) in the Average Cost per Cardiac Ward Bed Day, Average Cost of PCI Consumables per PCI, and average cost per PCI procedure. This breakdown would give the reader a clearer idea of which components contribute to the average costs and when comparing between facilities, where variations come from.
We provided the actual value of each of the component in Table 3 . However, the inclusion of % breakdown of each and every component produced a very busy table. As such, we tabulated the % breakdown only for the major components.
It would also be useful to have a comparison of the cost estimates with those from other studies.
We have added in a brief discussion on this matter in Discussion (Page 18). Thank you for the productive inputs in helping us improving the manuscript.
Main comments: 1. The main purpose of this manuscript seems to be to provide an example about a costing exercise (no final results are presented). In that case, I think that providing more details about the costing procedures would be useful for readers. For example, authors could show the total labor cost in the center that they analyzed, and show how they calculated the unit cost reported in table 2. They could do the same for each cost item in table 2. Data for each calculation could be provided in supplemental material, specifying the source of each data. Data to be reported should include total costs for each item considered, total number of bed-days, total number of PCI procedures performed, etc.
Similar concern was raised by Reviewer 2. We have taken the initiative to include more detailed information on the cost data collection in a new table (Table 2) .
Also, authors could provide more qualitative results about their experience, that help others to conduct a similar exercise in other settings. For example, do the authors found issues or barriers during the costing process in the centers that decided to participate? There were data that could not be estimated directly and that required expert opinion? This kind of results could be very valuable for readers, if the main focus of the manuscript is to provide an example about how costing could be conducted.
We did in fact face quite a few setbacks during the costing process. We addressed some of the issues in Discussion (Page 17 Paragraph 1).
2. Since data were collected from January to June 2014, it is not clear why final results are not presented as part of this manuscript. A manuscript including final results may have a greater audience. I would be particularly interested to see whether the PCI cost estimation is consistent across the 5 centers, or if there is a big variation. Could the authors explain why final results are not reported as part of this manuscript?
Please see our reply under the Editorial Comment.
Minor comments 3. Abstract. The sentence: "we included only patients who undergo PCI" could be confused for many readers. Stating that patients were included may lead to many readers to think that other kind of costing method was used. There are actually no "patients" included in this study, but rather healthcare centers. I would suggest to change the abstract to indicate that the unit of analysis are healthcare centers, and that the outcome was an elective PCI hospitalization cost.
We have amended the "Participants" and "Outcome Measures" sections in Abstract (Page 1).
As we have now modified our objectives and included the final cost calculation results of all centres, we decided not to make major changes to the Introduction.
5. In addition to PCI, there are other conditions that are being costed? It could be valuable for some readers to know that in the future you will be able to present costs for other conditions.
PCI was first in the pipeline of several other cardiac and non-cardiac conditions we intend to cost. The unit cost derived from this study can be applied for other CAD treatment (e.g. CABG, pharmacological fibrinolysis) and other interventional cardiology procedure (e.g. pacemaker insertion). We have highlighted this as recommendations for future research in Discussion (Page 18). This paragraph has since been removed as full results are reported in this revision.
9. Discussion: Again, it could be more focused on the main purpose of the manuscript. For example, discussion could include more details about the comparison with approaches for costing used in HIC. Some sentences in the methods section could be moved to the discussion (see my comment 6).
We have reshuffled some sentences from the Methods section to the Discussion to highlight how we overcame the limitations in our country setting in the conduct of an economic evaluation.
10. Below, I provide some questions that authors may consider to address in the discussion if they would like to provide insights to other investigators who want to conduct a costing study in other settings:
a. Do you think that the method you used would allow you to estimate the cost for multiple conditions easier than other costing methods (e.g., microcosting)?
Our top-down costing method is easier in terms of the time and manpower required. It will provide detailed baseline cost data to enable cost analysis, thus making it an attractive option in healthcare settings with no prior cost data available. However, we feel that microcosting should be incorporated for certain cost items that are likely to produce significant impact on the final cost.
b. Data collection was conducted between January and June 2014. Do you consider possible that it could be season variations for PCI costs in your analysis? For example, utilities or labor cost per bedday may vary if hospitals are full or empty, and this may change overtime or by season. Should be readers aware of this when costing different conditions?
We observed little fluctuation in the number of PCI procedure conducted throughout the previous years of 2011-2013. This observation was confirmed by interventional cardiologists in the team. Furthermore, as a tropical country, Malaysia is unlikely to be affected by the winter peak and summer trough in CAD incidence and mortality like most countries with temperate climates.
c. Generalizability: are you able to provide a description of the characteristics of patients who received elective PCI in the centers analyzed? For example, what was the mean age, how many stents did they receive in average, what percentage of bare-metal and drug-eluting stents were used? These are kind of data that could be very useful for those interested in using the costs that you estimated for future studies. Being able to know the characteristics of the population that you used to estimate the costs would help these researchers to understand whether your results could be generalized to their patients. However, you may have not been able to collect these information, which may be a limitation of this costing method.
We fully agree that the inclusion of clinical and treatment characteristics of patients at each centre will enable a more comprehensive cost comparison. We have addressed this issue and our plan for future research in the Discussion section (Page 18 Paragraph 2).
As PCI consumables were utilized in the CL, we would like to retain it as a cost item under the unit of analysis CL to avoid confusion. The separation from other general consumables in CL were made due to its high purchasing price and also the need for a different denominator to calculate its average cost. Please refer to Figure 2 and Table 2. 12. Figure 1 : There is not arrow going to the PCI consumables box.
Minor amendments made to the Pathway Figure. Please see Figure 2 .
VERSION 2 -REVIEW REVIEWER
Neha Batura University College London, UK REVIEW RETURNED 27-Mar-2017
GENERAL COMMENTS
All raised concerns have been addressed by the authors and the inclusion of the cost estimates from all the study sites has added value to this paper. My only suggestion would be to discuss some of the important findings in the Discussion section. At the moment, they are only highlighted in the Results section.
REVIEWER

Lisandro Colantonio
School of Public Health, University of Buenos Aires, Argentina REVIEW RETURNED 24-Mar-2017
GENERAL COMMENTS
Authors have made a good work addressing the comments provided by the reviewers, and the manuscript has improved substantially by including results from the 5 centers. However, I consider that there are 2 major issues that need to be addressed before publication.
Major comments. 1. 2. The manuscript needs to be revised for style and typos. There are minor grammar issues through the manuscript that diminish the importance of this work. For example, on Page 10, lines 28-30, the word available appears twice in the sentence: "Depending on the best available cost information available…". Also, on Page 16, lines 6-8, the word "service" is twice in the sentence: "service expansion of the cardiology service". 3. Page 6, line 39 of the PDF: could you report how many public and private cardiac centers were invited to collaborate in this study? 4. Page 8, lines 29-31: I would recommend changing "simple sense check" for "face validity check". 5. Table 2 : can authors describe costs items for CW and CL, separately? This will be more consistent with what is described in the Methods section. 6. As I commented on my first revision, I will recommend authors to shorten and focus the manuscript. A manuscript which is easy to read and has a single and clear main message will reach a greater audience and have more citations. For example, the introduction is long. The second paragraph of the introduction is about the burden of CVD in Malaysia, which is not the main focus of this manuscript. Then authors need the third paragraph to go from CVD to why study PCI. Authors could have only 1 paragraph stating that PCI is a common procedure for patient with CHD, however, this is expensive and therefore, costs associated with these procedures are important for local health decision and policy makers (or something similar along these lines). Other example, the last sentences on the third paragraph of the introduction are about that costs of procedures could be different across different hospitals, and then authors provide some supporting evidence. These sentences could be deleted as I don"t imagine someone will argue against that costs may differ across different centers. The introduction should focus on the main reasons why you conduct this study. Ultimately, I defer the decision on whether the manuscript should be shortened to the authors and the Editorial board since a long manuscript does not reduce the validity of results reported. Authors have made a good work addressing the comments provided by the reviewers, and the manuscript has improved substantially by including results from the 5 centers. However, I consider that there are 2 major issues that need to be addressed before publication.
VERSION 2 -AUTHOR RESPONSE
Major comments. 1. --> There has been some major oversight when we transferred the results from Excel file to the Word Table. The denominators for CW admission (total bed days) for Centre II-V were mixed up, thus leading to the miscalculations. Our apologies for not checking it through in the previous submission.
2. I do not agree with the sentence "results showed that daycare establishment can be an attractive cost-saving strategy". First, there is only 1 center (Center III) with daycare included in the analysis, and we don"t know if the same finding will be present in other centers with daycare (if any).
--> There is a limited number of Malaysian public cardiac centres providing daycare facility. The establishment of daycare centre for same-day discharge for cardiac patients who undergo interventional procedures such as PCI only became more common in the past 3-5 years. Furthermore, due to the small sample size of our study centres, we only managed to compare the cost per bed day within the same centre that provide both inpatient and daycare setting for PCI patients. Nevertheless, we have amended the above-mentioned sentence. We have also highlighted the need for further research on this issue in Paragraph 5 of Discussion.
Second, there is actually no evidence that the daycare has contributed to the lower cost observed in Center III. If we compared the average cost per bed day in Center III, this is higher for daycare versus inpatient care (818.53 versus 647.87, respectively). Are these numbers correct? Can the authors explain this finding? Third, average cost per bed day is lower in Center IV (479.59) than in Center III.
--> The initial Table 2 contained some errors due to the above-mentioned miscalculations. In the new Table 2 , the cost per bed day is lower for Daycare (RM 479.59) compared to inpatient setting (RM 818.53) in Centre III. It is also the lowest cost per bed day among all centres. Forth, Center III had the lower CL cost (including PCI) across centers, which represents the 85% of the total cost. This suggests that other factors (CL) may be more important in the lower cost observed in Center III. I will suggest to remove from the abstract and the conclusion that daycare may be costsaving for PCI, as this is not supported by the current analysis.
--> This costing analysis was conducted from the perspective of 2 units of analysis. We agree that overall, the second unit of analysis-procedural cost of PCI in CL, especially the cost of PCI consumables was the dominant cost driver. We have also proposed cost containment strategies with regard to this. If we focus on analysis from the first unit of analysis-CW admission, daycare facility is indeed a potential cost saving option judging from the lowest cost of admission incurred across all centres. We have made minor modification to the abstract but we would like to maintain our viewpoint on daycare establishment in the Discussion and Conclusion. 1.
The title should be updated. The manuscript does not only provide the methods and rational for a cost study, and does not only describe the study design. A title like "Cost of Elective Percutaneous Coronary Intervention in Malaysia, a Multi-Centre Cross Sectional Costing Study" seems more appropriate for the revised manuscript.
--> We have revised the title accordingly.
2.
The manuscript needs to be revised for style and typos. There are minor grammar issues through the manuscript that diminish the importance of this work. For example, on Page 10, lines 28-30, the word available appears twice in the sentence: "Depending on the best available cost information available…". Also, on Page 16, lines 6-8, the word "service" is twice in the sentence: "service expansion of the cardiology service".
--> We have corrected the grammatical errors as pointed out and also revised certain sections of the manuscript.
3.
Page 6, line 39 of the PDF: could you report how many public and private cardiac centers were invited to collaborate in this study?
--> Amendment made.
4.
Page 8, lines 29-31: I would recommend changing "simple sense check" for "face validity check".
5.
Table 2: can authors describe costs items for CW and CL, separately? This will be more consistent with what is described in the Methods section.
--> We decided to maintain the current layout of Table 2 . To describe the 2 units of analysis separately will lead to redundancy in the explanation of many cost items. We feel that the existing Table 2 is a good complement to the Methods section of Step 3 Valuation of Cost Items.
6.
As I commented on my first revision, I will recommend authors to shorten and focus the manuscript. A manuscript which is easy to read and has a single and clear main message will reach a greater audience and have more citations. For example, the introduction is long. The second paragraph of the introduction is about the burden of CVD in Malaysia, which is not the main focus of this manuscript. Then authors need the third paragraph to go from CVD to why study PCI. Authors could have only 1 paragraph stating that PCI is a common procedure for patient with CHD, however, this is expensive and therefore, costs associated with these procedures are important for local health decision and policy makers (or something similar along these lines). Other example, the last sentences on the third paragraph of the introduction are about that costs of procedures could be different across different hospitals, and then authors provide some supporting evidence. These sentences could be deleted as I don"t imagine someone will argue against that costs may differ across different centers. The introduction should focus on the main reasons why you conduct this study. Ultimately, I defer the decision on whether the manuscript should be shortened to the authors and the Editorial board since a long manuscript does not reduce the validity of results reported.
--> We agree that the Introduction was rather lengthy. We have made the necessary edition to reduce the word count of the manuscript.
